Biotech Breakthroughs: Paths to Affordable Healthcare and Global Equity

Spokesperson: Gonzalo Ladreda, CEO & Cofounder, Upfront Diagnostics

At UpFront Diagnostics, we believe lateral flow technology has played a huge role in saving lives.

Lateral flow technology is the same simple, affordable format that proved its value during COVID-19 and can now be applied to one of medicine’s most time-critical emergencies: stroke. That pandemic proved that when minutes determine outcomes, centralized lab processing becomes a bottleneck. Stroke faces the same reality, except the stakes are brain cells, not case counts — “time is brain,” and every minute of delay costs a patient’s ability to speak, walk, or live independently.

Traditional stroke diagnosis relies on lab assays and imaging that require centralized hospital processing and hours of turnaround. That works inside a well-resourced hospital. It fails everywhere else — ambulances, rural clinics, and the majority of healthcare settings globally without 24/7 access to CT or MRI.

Lateral flow solves this at every level; it’s a test that needs neither power nor a data connection and can be used anywhere: an ambulance, a rural clinic, a district hospital without a radiology suite.

A rare combination of speed, affordability, and infrastructure independence is what makes this an equity story, not just a technology story. Just as a stroke doesn’t wait for a patient to reach a well-equipped hospital, diagnosis shouldn’t either. Moving detection out of the centralized lab and into frontline hands means extending accurate diagnosis to settings that currently have none.

Global health equity here isn’t abstract. It’s the difference between a patient reaching the right treatment pathway in time, whether they collapsed in a city center or a village with no scanner. Affordable, infrastructure-free diagnostics don’t just make healthcare faster for those who already have access — they close the gap for those who don’t. That’s what a truly equitable diagnostic tool should do: work the same way, at the same speed, regardless of where a patient happens to be.

One innovative approach we have taken is to make biotech research and manufacturing materials more active/potent and consistent so that the end user can significantly improve manufacturing output and reduce failures and material usage. The materials that I am working on particularly have a profound impact on advanced and emerging cancer and autoimmune disease therapies such as cell therapy and regenerative medicine.

My company specifically works to help get new medical devices and technologies to market faster. We help people navigate the regulatory process, which is confusing, complicated, and long, getting new devices and technology through that process as fast and successfully as possible. All the while, we also prioritize patient safety, working hard to ensure that the devices and technology we are helping through the process are what they claim to be and have all of the proper testing required. If we can get innovative new technology and devices to market sooner, that ultimately helps with accessibility by getting the people who need those things most access to them as quickly as possible.

I should be straight about my seat here. I am a consumer brand founder, so I sit downstream of biotech, at the point where a compound that came out of a lab has to reach an ordinary person at a price they can afford every month.

That distance is where most of the cost hides. The ingredients we work with at APMZEE were, until fairly recently, things you met through a private clinic or a specialist supplier at a price built for early adopters. Our approach was to design the product around a monthly cost first and work backwards, which meant committing to bigger production runs earlier than felt comfortable, holding fewer product lines so each one carried real volume, and selling direct so nobody in the middle needed a margin. Doing that took roughly 30% out of our cost per month compared with our first small batch, and that saving is the whole difference between a curiosity and something a person keeps buying in month seven.

On health equity, I would rather understate it. Supplements sit at the edge of that conversation, and I will not claim more than the category deserves. What I would say is that pricing is a design decision made at the start, and any science that only exists at clinic prices stays available to the people who were already fine.

In my building, affordability is decided by whether the answer arrives before the patient leaves.

The sticker price of a test is rarely what stops somebody. The second trip is. Another half day off work, another bus fare, another childcare arrangement, and a result that now needs a phone call to explain. That is where people fall out of the process, and they fall out quietly, so nobody records it as a cost.

So my rule for any technology I bring into the practice is that it has to close the loop inside the visit that is already happening. If a device gives us an answer while the person is still in the room, I look at it seriously. If it starts a second appointment, it has to earn that, and mostly it does not.

The other half is money. Our in-house testing sits inside what people already pay rather than being billed separately, so nobody is doing arithmetic in their head at the moment of care. About 30 patients a month avoid a return trip because of that arrangement.

None of this is a comment on how any result should be read, which belongs with the labs and the specialists. It is the boring logistics layer, and I would argue it decides access more often than the technology does.